Liposomal irinotecan+5-fluorouracil plus leucovorin plus bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study
机构:[1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[2]Shanxi Cancer Hospital, Taiyuan, Shanxi, China[3]Shanxi Tumor Hospital, Taiyuan, China[4]Jiangxi Cancer Hospital, Nanchang, Jiangxi, China[5]Jiangsu Province Hospital, Nanjing, Jiangsu, China江苏省人民医院[6]Department of Colorectal Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin, China[7]Tangshan People's Hospital, Tangshan, China[8]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China江苏省人民医院[9]Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China[10]The Second Hospital of Hebei Medical University, Shijiazhuang, China
第一作者机构:[1]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
推荐引用方式(GB/T 7714):
Hu Xuhua,Jiang Bo,Hongxia Lu,et al.Liposomal irinotecan+5-fluorouracil plus leucovorin plus bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study[J].JOURNAL OF CLINICAL ONCOLOGY.2025,43(4_SUPPL):195-195.doi:10.1200/JCO.2025.43.4_suppl.195.
APA:
Hu, Xuhua,Jiang, Bo,Hongxia, Lu,Yu, Bin,Yi, Bo...&Wang, Guiying.(2025).Liposomal irinotecan+5-fluorouracil plus leucovorin plus bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.JOURNAL OF CLINICAL ONCOLOGY,43,(4_SUPPL)
MLA:
Hu, Xuhua,et al."Liposomal irinotecan+5-fluorouracil plus leucovorin plus bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study".JOURNAL OF CLINICAL ONCOLOGY 43..4_SUPPL(2025):195-195